Combination therapies might therefore elevate the response rates in FGFR2amp tumours, as proposed for FGFRi–CDK4/6i combination therapy in patients with breast cancer with FGFR2 and CCND1 amplifications50. The gene discussed is CCND1; the disease is breast carcinoma.